OKYO
NASDAQOKYO Pharma Limited
Price$1.56-0.06 (-3.70%)
01:30 PM07:45 PM
News · 26 weeks55+133%
2025-12-142026-06-07
Mix2390d
- SEC Filings8(35%)
- Insider7(30%)
- Other4(17%)
- M&A3(13%)
- Leadership1(4%)
Latest news
25 items- INSIDERSEC Form 3 filed by new insider Denoyer Bernard3 - OKYO Pharma Ltd (0001849296) (Issuer)
- INSIDERNew insider Simon Willy Jules claimed ownership of 15,383 shares (SEC Form 3)3 - OKYO Pharma Ltd (0001849296) (Issuer)
- INSIDERNew insider Brancaccio John P claimed ownership of 30,201 shares (SEC Form 3)3 - OKYO Pharma Ltd (0001849296) (Issuer)
- INSIDERNew insider Shah Keeren Rameshchandra claimed ownership of 16,667 shares (SEC Form 3)3 - OKYO Pharma Ltd (0001849296) (Issuer)
- INSIDERSEC Form 3 filed by new insider Dempsey Robert John3 - OKYO Pharma Ltd (0001849296) (Issuer)
- SECSEC Form 6-K filed by OKYO Pharma Limited6-K - OKYO Pharma Ltd (0001849296) (Filer)
- PROKYO Expands Scientific Advisory Board with the Appointment of International Expert Marta Sacchetti, MD, PhDDr. Sacchetti brings international expertise in clinical and translational research on ocular inflammatory and degenerative diseaseOKYO's introduction to the broader ophthalmology community at ASCRS drove strong engagement at Eyecelerator and ARVO LONDON and NEW YORK, May 19, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and for inflammatory eye diseases, today announced the expansion of their Scientific Advisory Board (SAB) with the appointment of Marta Sacchetti, MD, PhD. This appointment further enhances the Company's global scientific netwo
- SECSEC Form SCHEDULE 13G filed by OKYO Pharma LimitedSCHEDULE 13G - OKYO Pharma Ltd (0001849296) (Subject)
- SECSEC Form 6-K filed by OKYO Pharma Limited6-K - OKYO Pharma Ltd (0001849296) (Filer)
- PROKYO CEO and CSO to Present and Leadership Team to Participate at Upcoming Scientific Conferences in MayRobert J. Dempsey, MBA, Chief Executive Officer, to present at EyeceleratorRaj Patil, PhD, Chief Scientific Officer, to present at ARVO LONDON and NEW YORK, April 29, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and for inflammatory eye diseases, today announced CEO presentation at Eyecelerator and leadership participation at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting in Denver, Colorado. Upcoming Scientific Conferences: Eyecelerator: May 1, 2026Denver, Colorado Presentation Title: Addressing Unmet Needs
- SECSEC Form 6-K filed by OKYO Pharma Limited6-K - OKYO Pharma Ltd (0001849296) (Filer)
- PROKYO Pharma Announces Scientific Advisory Board Meeting and Urcosimod Data Presentation During ASCRS Annual MeetingLONDON and NEW YORK, April 07, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ:OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and for inflammatory eye diseases, today announced that it will hold a key Scientific Advisory Board (SAB) meeting with leading ophthalmology experts during the 2026 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting in Washington, DC. The SAB meeting, scheduled to take place alongside the conference, will bring together prominent corneal and ocular surface disease specialists to review clinical data for the company's lead candidate, urcosimod and
- SECSEC Form 6-K filed by OKYO Pharma Limited6-K - OKYO Pharma Ltd (0001849296) (Filer)
- PROKYO Pharma Announces Chairman and Founder Acquires SharesLONDON and NEW YORK, March 19, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and for inflammatory eye diseases, today announced it has been informed that Panetta Partners Limited, an entity in which Gabriele Cerrone, the Executive Chairman, has a beneficial interest, has acquired 10,119 of the Company's ordinary shares on NASDAQ at $1.59, bringing his total holding to 10,526,416 shares. About Urcosimod (formerly called OK-101) Urcosimod is a lipid conjugated chemerin peptide agonist of the ChemR23 G-protein coupled receptor which is typically
- SECSEC Form 6-K filed by OKYO Pharma Limited6-K - OKYO Pharma Ltd (0001849296) (Filer)
- PROKYO Pharma Announces Director Acquires SharesLONDON and NEW YORK, March 19, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and for inflammatory eye diseases, today announced it has been informed that John Brancaccio, Non-Executive Director, has acquired 5,000 of the Company's ordinary shares on NASDAQ at $1.61, bringing his total holding to 31,201 shares. About Urcosimod (formerly called OK-101) Urcosimod is a lipid conjugated chemerin peptide agonist of the ChemR23 G-protein coupled receptor which is typically found on immune cells of the eye responsible for the inflammatory response, as
- SECSEC Form 6-K filed by OKYO Pharma Limited6-K - OKYO Pharma Ltd (0001849296) (Filer)
- PROKYO Pharma Announces Chief Development Officer and Director Acquires SharesLONDON and NEW YORK, March 19, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ:OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and for inflammatory eye diseases, today announced it has been informed that Gary Jacob, Chief Development Officer and Director, has acquired 30,980 of the Company's ordinary shares on NASDAQ at $1.59, bringing his total holding to 108,920 shares. About Urcosimod (formerly called OK-101) Urcosimod is a lipid conjugated chemerin peptide agonist of the ChemR23 G-protein coupled receptor which is typically found on immune cells of the eye responsible for the inflammat
- INSIDERSEC Form 3 filed by new insider Jacob Gary S3 - OKYO Pharma Ltd (0001849296) (Issuer)
- INSIDERSEC Form 3 filed by new insider Cerrone Gabriele M3 - OKYO Pharma Ltd (0001849296) (Issuer)
- SECSEC Form 6-K filed by OKYO Pharma Limited6-K - OKYO Pharma Ltd (0001849296) (Filer)
- PROKYO Pharma Reports New Phase 2 Data Demonstrating Meaningful Improvements in Patient-Reported Quality of Life Outcomes with Urcosimod in Neuropathic Corneal PainLONDON and NEW YORK, March 18, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and for inflammatory eye diseases, today announced new positive findings from an exploratory analysis of patient-reported outcomes in its recently completed Phase 2a trial of urcosimod (0.05%) for the treatment of NCP. This new quality-of-life (QoL) data will be presented at the Association for Research in Vision and Ophthalmology (ARVO) 2026 Annual Meeting. The presentation, titled: "First-in-Human Study of Urcosimod to Treat Neuropathic Corneal Pain (NCP) Shows Clinic
- SECSEC Form 6-K filed by OKYO Pharma Limited6-K - OKYO Pharma Ltd (0001849296) (Filer)
- SECSEC Form 6-K filed by OKYO Pharma Limited6-K - OKYO Pharma Ltd (0001849296) (Filer)
- PROKYO Abstract Selected for Presentation at Premier Global Ophthalmology CongressLONDON and NEW YORK, Feb. 23, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ:OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and for inflammatory eye diseases, today announced that its abstract has been accepted for presentation at the Association for Research in Vision and Ophthalmology (ARVO) 2026 Annual Meeting, taking place May 3-7, 2026, in Denver, Colorado. Chief Scientific Officer Raj Patil, Ph.D., will share the data in a presentation titled: "First-in-Human Study of Urcosimod to Treat Neuropathic Corneal Pain (NCP) Shows Clinically Meaningful Pain Reduction and Quality-of-Life Improve
OKYO FAQ
7 questionsWhat does OKYO Pharma Limited do?
OKYO Pharma Limited, a preclinical biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. It is developing OK-101 for the treatment of dry eye disease; and OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic ocular pain. The company is also developing chemerin and chemerin analogues to treat the cytokine release syndrome associated with COVID-19 infections and other conditions, such as acute respiratory distress syndrome. OKYO...Where does OKYO stock trade?
OKYO Pharma Limited (OKYO) is listed on NASDAQ.What sector and industry is OKYO in?
OKYO Pharma Limited operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did OKYO Pharma Limited go public?
OKYO Pharma Limited (OKYO) completed its IPO in 2022.What are analysts saying about OKYO?
OKYO Pharma Limited has had 2 recent analyst actions on file. The most recent action was from Piper Sandler: Overweight with a $700.00 price target on 2026-02-20. Recent price targets range from $500.00 to $700.00.What companies are similar to OKYO?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.), BIIB (Biogen Inc.). Compare OKYO side-by-side with any of them on Quantisnow.How can I track OKYO on Quantisnow?
Quantisnow aggregates OKYO Pharma Limited's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow OKYO to receive live email and push alerts on every new disclosure.